- Ligand Pharmaceuticals (LGND) on Thursday announced a financing agreement worth up to $47M with privately held AvenCell Therapeutics to help advance AvenCell’s pipeline of CAR-T cell therapies.
- Cambridge, Massachusetts-based AvenCell’s lead asset is AVC-201, an anti-CD123 CAR-T undergoing a Phase 1b expansion
Ligand, AvenCell financing deal worth up to $47M (LGND:NASDAQ)
